All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Bortezomib Retreatment Is Effective in Relapsed Multiple Myeloma Patients - Real-Life Clinical Practice Data

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025LQ" target="_blank" >RIV/61988987:17110/20:A21025LQ - isvavai.cz</a>

  • Result on the web

    <a href="https://pubmed.ncbi.nlm.nih.gov/31829027/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/31829027/</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4149/neo_2019_190430N383" target="_blank" >10.4149/neo_2019_190430N383</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Bortezomib Retreatment Is Effective in Relapsed Multiple Myeloma Patients - Real-Life Clinical Practice Data

  • Original language description

    Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. The aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7–8.9), median duration of response was 10.5 months (95% CI: 8.0–13.0) and median overall survival was 20.3 months (95% CI: 17.9–22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Neoplasma

  • ISSN

    1338-4317

  • e-ISSN

  • Volume of the periodical

    67

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    SK - SLOVAKIA

  • Number of pages

    6

  • Pages from-to

    178-184

  • UT code for WoS article

    000542659200021

  • EID of the result in the Scopus database